ČERVINEK, Libor, Jiří MAYER and Michael DOUBEK. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. International journal of hematology. Tokyo: Springer Japan KK, 2015, vol. 102, No 1, p. 7-11. ISSN 0925-5710. doi:10.1007/s12185-015-1793-1.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults
Authors ČERVINEK, Libor (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Michael DOUBEK (203 Czech Republic, guarantor, belonging to the institution).
Edition International journal of hematology, Tokyo, Springer Japan KK, 2015, 0925-5710.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Japan
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.846
RIV identification code RIV/00216224:14740/15:00085026
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1007/s12185-015-1793-1
UT WoS 000358146600002
Keywords in English Immune thrombocytopenia; Thrombopoietin-receptor agonists; Remission; Sustained response
Tags EL OK, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Eva Špillingová, učo 110713. Changed: 4. 4. 2016 13:48.
Abstract
Thrombopoietin-receptor agonists (TPO-RAs) are highly effective in immune thrombocytopenia (ITP). Recently, reports of sustained remission after TPO-RA discontinuation in adult ITP have been reported. We aimed to describe the subset of patients in whom TPO-RA therapy may induce a durable response. We retrospectively analyzed all of our adult ITP patients treated with TPO-RAs, and focused on patients with discontinued TPO-RA therapy due to treatment response. Forty-six relapsed or refractory ITP patients were treated with TPO-RAs. In 11 of these cases, TPO-RA therapy (seven romiplostim; four eltrombopag) was stopped after achieving treatment response. No side effects of TPO-RAs were observed. These patients were pretreated with 1-3 therapy lines plus splenectomy in six patients prior to TPO-RA administration. None of these patients experienced disease relapse after therapy discontinuation over a median follow-up of 33 months (16-54). Substantial proportion of ITP patients receiving TPO-RAs can maintain a durable response after treatment discontinuation. Sustained ITP remission probably does not depend on previous treatment, splenectomy, or disease duration.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
PrintDisplayed: 20. 5. 2022 23:35